Close menu




November 28th, 2024 | 07:15 CET

Barrick Gold, Desert Gold, Novo Nordisk - How political decisions and market opportunities drive prices

  • Mining
  • Gold
  • Healthcare
Photo credits: Barrick Gold Corp.

The capital markets are again demonstrating how closely intertwined political decisions, external market factors, and entrepreneurial skills are. The planned expansion of Medicare and Medicaid coverage of obesity drugs could open up new growth prospects for the Danish pharmaceutical giant Novo Nordisk in the US. However, the wind of change is blowing in the direction of a new administration with a strong reputation in the US healthcare sector. Industry giant Barrick Gold shines with impressive numbers, with operating cash flow alone at USD 23 billion. Meanwhile, explorer Desert Gold is securing fresh capital through clever financing for its promising SMSZ gold project in Mali, Africa. Here is what investors should be looking out for now.

time to read: 4 minutes | Author: Juliane Zielonka
ISIN: BARRICK GOLD CORP. | CA0679011084 , DESERT GOLD VENTURES | CA25039N4084 , NOVO NORDISK A/S | DK0062498333

Table of contents:


    Jared Scharf, CEO, Desert Gold Ventures Inc.
    "[...] We have already discovered 1.1 million ounces of gold on our 440 km2 flagship SMSZ Project and our stock market value is currently around USD 10.60 per troy ounce in the ground. [...]" Jared Scharf, CEO, Desert Gold Ventures Inc.

    Full interview

     

    Barrick Gold impresses with a strong balance sheet and growth projects

    The gold mining and production company Barrick Gold is in excellent shape. At an investor conference in New York, CEO Mark Bristow gave an extremely positive summary of the past few years. Since the last major merger, the Company has generated an operating cash flow of USD 23 billion and invested USD 15 billion in the Company's future.

    The solid financial policy is paying off: net debt fell by almost USD 4 billion, while shareholders shared in the success with distributions of more than USD 5 billion. Bristow emphasizes that the investments made will secure production for at least ten years – an important aspect for long-term planning.

    A particular highlight is the Fourmile project, which is wholly owned by Barrick. Initial economic analysis indicates that operational cash flows could exceed those of the already successful neighboring Goldrush project by at least 70%. The other mine expansions in Nevada, including Leeville, Hanson, Robertson, Swift and Turquoise Ridge, are also developing well.

    Desert Gold secures millions in financing as gold prices rise

    Desert Gold Ventures Inc. is securing a significant inflow of capital in a market environment characterized by record gold prices. The Company has raised CAD 1.26 million through the exercise of 15,728,571 warrants to raise CAD 1.26 million. These funds will be used primarily for the development of the flagship SMSZ project in West Mali and for general working capital.

    The timing of the financing appears favorable as the gold price has performed remarkably well this year. In the eurozone, gold is up 33% year-to-date and recently reached a new all-time high at EUR 2,607.99 per troy ounce. This development is mainly driven by the weakness of the euro and geopolitical uncertainties.

    Under the incentive program that Desert Gold Ventures previously announced in September and October 2024, participating holders received additional warrants in the same amount. These new warrants can be exercised at CAD 0.08 per share for a period of three years. A special clause allows the Company to accelerate the maturity with 30 days' notice if the share price on the TSX Venture Exchange is at or above CAD 0.20 for ten consecutive trading days.

    Desert Gold Ventures Inc. controls the 440 km2 SMSZ project in western Mali. Measured and indicated mineral resources total 8.47 million tonnes, grading 1.14 g/t Au for a total of 310,300 ounces. Inferred Mineral Resources are estimated at 20.7 Mt grading 1.16 g/t Au for a total of 769,200 ounces.

    The successful completion of the warrant program strengthens the Company's financial position in a market environment characterized by rising gold prices and robust demand.

    Biden plan boosts Novo Nordisk - Shares rise sharply

    Pharmaceutical companies Novo Nordisk and Eli Lilly are seeing significant share price gains following a landmark proposal by the US government to cover the costs of obesity drugs. According to Reuters, Novo Nordisk's shares rose by 4.9% at times, while Eli Lilly's shares rose by more than 3%.

    Outgoing US President Joe Biden plans to significantly expand coverage of obesity drugs in the state health programs Medicare and Medicaid. For millions of Americans, co-payments for these drugs could decrease by up to 95%. The new regulations could take effect in 2026. However, this measure does not address the root of the problem: unhealthy diets, lack of exercise and portion sizes have led many Americans to obesity.

    The stock market, on the other hand, is pleased. Even at the expense of the competition, the positive market reaction was further strengthened by disappointing study results from competitor Amgen. Its experimental drug MariTide only achieved an average weight reduction of up to 20% in a phase II study – a figure that fell short of market expectations.

    Alexander Jenke, Portfolio Manager at Medical Strategy in Munich, sees the planned expansion of coverage as a logical consequence of the positive study results, particularly regarding the cardiovascular benefits of Novo Nordisk's Wegovy. However, he points out the uncertainty regarding how future US governments will deal with this policy. What also remains in the dark: long-term studies. These do not yet exist due to the approvals of the two active ingredients. US President-elect Donald Trump has also appointed the health economist Dr. Jay Bhattacharya​​, a critic of pandemic lockdowns and vaccine mandates, as Head of the National Institutes of Health, the country's leading medical research agency. This appointment will undoubtedly shake up the US pharmaceutical market.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author



    Related comments:

    Commented by Juliane Zielonka on February 6th, 2025 | 08:30 CET

    Palantir, First Phosphate, BYD – AI, battery raw materials, and e-mobility are driving growth

    • Mining
    • phosphate
    • Software
    • AI
    • Electromobility

    Fresh quarterly figures and new projects for the electrified world shape this week's stock market. Palantir is posting impressive quarterly figures and achieving new price jumps on the stock market. Investors can expect further growth from the US company with the DOGE project from Trump and Musk. DOGE is streamlining bureaucratic structures, a huge opportunity for Palantir. Raw material producer First Phosphate is positioning itself in the booming market for LFP batteries and is planning sustainable large-scale production of battery raw materials in Canada. Meanwhile, Chinese electric automaker BYD is strengthening its presence in Germany with the appointment of an experienced domestic sales director and setting ambitious sales targets of 50,000 vehicles per year. The details.

    Read

    Commented by Fabian Lorenz on February 6th, 2025 | 07:40 CET

    GOLD and ARMAMENTS unstoppable: Renk outperforms Hensoldt – Barrick Gold and First Nordic Metals with MOMENTUM

    • Mining
    • Gold
    • Commodities
    • Defense

    Gold and defense stocks are currently unstoppable. The gold price is now well above the USD 2,800 mark. Just in time for the record price, insider tip First Nordic Metals is starting its drilling program in Sweden. The stock has taken off, and investors can look forward to a lively news flow. Even gold giant Barrick is sending positive signals, and the stock is picking up momentum. "Gold has truly arrived as the ultimate store of value," the Barrick CEO said in an interview with Bloomberg. Defense stocks are also completely unfazed by Donald Trump's tariff threats. While Rheinmetall is trading at an all-time high, Renk seems to be leaving the downward trend behind and finally catching up. Hensoldt's performance is clearly being surpassed. Will the momentum continue?

    Read

    Commented by Fabian Lorenz on February 6th, 2025 | 07:20 CET

    Puma, Nordex, and Power Nickel - Potential for a price jump? Analysts see opportunities in these stocks

    • Mining
    • Nickel
    • Gold
    • Commodities
    • renewableenergies
    • Sportswear

    Power Nickel's shares were among the commodity high flyers of 2024. The upward trend appears to be continuing in the new year. Power Nickel's high-grade Nisk project is increasingly turning into a gold mine with numerous valuable metals. To increase its value further, it will continue to drill and spin off non-core activities. Will analysts soon be raising their price targets? Puma shareholders have been waiting in vain for a price jump for quite some time. The sporting goods company is caught in a margin trap. The target prices are widely divergent. After difficult years, Nordex is actually doing well. But the US is becoming more and more of a concern. And now there is also a headwind in Germany.

    Read